Andrew Lam, Pharm.D. is a Senior Vice President at Ally Bridge Group, a leading global life science-dedicated investment group, where he leads private equity therapeutics investments which include Arbor Biotechnologies, Shoreline Biosciences, and Sonoma Biotherapeutics. Andrew has over 15 years of biopharma-focused experience across industry, equity research, and investment banking and joined Ally Bridge Group in 2021 from Intercept Pharmaceuticals where he was Senior Director of Business Development. Prior to Intercept, Andrew was Vice President, Healthcare Investment Banking at Jefferies where he completed over 30 biopharma financing and M&A transactions, and equity research associate at BMO Capital and Canaccord Genuity, where he covered biotech. Prior to Wall Street, Andrew spent a decade in medical affairs at several biotech companies including Celgene and Shire.  Andrew holds a Pharm.D. from Long Island University and M.B.A. from Drexel University.